N/A
Completed N=1,021
Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
Source: ClinicalTrials.gov NCT03727139 ↗Enrolled (actual)
1,021
Serious AEs
12.6%
Results posted
Mar 2024
Primary outcomePrimary: Number of Participants Who Had One or More Adverse Events — 304 Participants
Summary
The purpose of this survey is to evaluate the long-term safety of Rasagiline (AZILECT) in patients with Parkinson's disease in daily clinical practice and also collect efficacy information.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Had One or More Adverse Events |
304 | — |
| PRIMARY Number of Participants Who Had One or More Adverse Drug Reactions |
189 | — |
| SECONDARY Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) |
-2.7 | — |
Eligibility Criteria
Inclusion Criteria
-Patients with Parkinson's disease should be surveyed.
Exclusion Criteria
-Participants who have contraindications on package insert of rasagiline.
Data sourced from ClinicalTrials.gov (NCT03727139). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.